When 11-year-old Luca from Aosta Valley was finally given a genetic diagnosis after years of uncertainty, his mother wept—not just for the answer, but for the relief of knowing his struggles had a name. His story is one of 29 families in northwestern Italy who, after years of medical odysseys, now have clarity, thanks to a groundbreaking study using whole-genome sequencing. Conducted in the Aosta Valley, the research marks Italy’s first large-scale application of this technology for neurodevelopmental disorders, offering hope to families long adrift in diagnostic limbo.
Neurodevelopmental conditions like autism spectrum disorder and intellectual disability affect about 1% of Italian children aged 7 to 9, yet pinpointing their causes has remained a profound challenge. Symptoms vary widely, and traditional testing often falls short. To bridge this gap, scientists from the Italian Institute of Technology’s Center for Clinical and Computational Genomics (C3G) and the Azienda USL of Aosta Valley launched the 5000genomi@VdA project in May 2022. They analyzed the full genomes of 110 children with neurodevelopmental disorders and both parents—300 individuals in total—seeking answers hidden in the 3 billion base pairs of human DNA.
The results were transformative. From approximately 26 million genetic variants identified, researchers zeroed in on those with clinical significance. Using advanced AI algorithms, they linked specific DNA changes to the children’s conditions, delivering definitive genetic diagnoses for 29 families. For many, this ended a years-long search for understanding. Among the discoveries was a previously unrecognized mutation in the KALRN gene in a young patient with autism and motor difficulties—a gene critical for neuron development, but never before tied to such disorders. This finding not only explained the child’s condition but also expanded the scientific community’s knowledge of the genetic architecture behind neurodevelopment.
"One of the most meaningful results of this study was that we were able to provide long-awaited answers to many families by identifying the genetic cause of their condition," said Dr. Laure Obino, director of the Complex Structure of Child Neuropsychiatry at the regional health authority. Those answers are more than academic—they shape care plans, inform inheritance risks, and can prevent unnecessary tests. Beyond diagnosis, the study unearthed several genetic alterations in genes not previously associated with neurodevelopmental disorders, opening new pathways for research and potential therapies.
As the data from the 5000genomi@VdA project continues to be analyzed, its ripple effects are already being felt. Clinicians across Italy are taking note, and families like Luca’s are no longer navigating the dark. This blend of cutting-edge genomics, artificial intelligence and compassionate care is not just advancing medicine—it’s restoring dignity, one diagnosis at a time. And as science decodes more of the genome, the future for children with neurodevelopmental disorders is becoming a little clearer, one gene at a time.